ZA200806946B - Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect - Google Patents

Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Info

Publication number
ZA200806946B
ZA200806946B ZA200806946A ZA200806946A ZA200806946B ZA 200806946 B ZA200806946 B ZA 200806946B ZA 200806946 A ZA200806946 A ZA 200806946A ZA 200806946 A ZA200806946 A ZA 200806946A ZA 200806946 B ZA200806946 B ZA 200806946B
Authority
ZA
South Africa
Prior art keywords
cicatrising
medicament
manufacture
triazine derivatives
angiogenic effect
Prior art date
Application number
ZA200806946A
Other languages
English (en)
Inventor
Moinet Gerard
Cravo Daniel
Original Assignee
Poxel Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel Sas filed Critical Poxel Sas
Publication of ZA200806946B publication Critical patent/ZA200806946B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200806946A 2006-01-13 2008-08-12 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect ZA200806946B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.

Publications (1)

Publication Number Publication Date
ZA200806946B true ZA200806946B (en) 2009-11-25

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806946A ZA200806946B (en) 2006-01-13 2008-08-12 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Country Status (22)

Country Link
US (1) US8217040B2 (xx)
EP (1) EP1971329B1 (xx)
JP (1) JP2009523140A (xx)
KR (1) KR101482686B1 (xx)
CN (1) CN101355931A (xx)
AR (1) AR059034A1 (xx)
AU (1) AU2006334732B2 (xx)
BR (1) BRPI0620983B8 (xx)
CA (1) CA2636838C (xx)
CY (1) CY1119872T1 (xx)
DK (1) DK1971329T3 (xx)
EA (1) EA016127B1 (xx)
ES (1) ES2647912T3 (xx)
FR (1) FR2896161B1 (xx)
HU (1) HUE037217T2 (xx)
IL (1) IL192595A (xx)
LT (1) LT1971329T (xx)
PL (1) PL1971329T3 (xx)
PT (1) PT1971329T (xx)
SI (1) SI1971329T1 (xx)
WO (1) WO2007079915A2 (xx)
ZA (1) ZA200806946B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US11617754B2 (en) 2017-10-02 2023-04-04 Poxel Sa Methods of treating heart failure with preserved ejection fraction
KR20200130281A (ko) 2018-06-06 2020-11-18 메타반트 사이언시스 게엠베하 당뇨병과 만성 신장 질환을 갖는 대상체를 치료하는 방법
CN112218623A (zh) 2018-06-14 2021-01-12 博希尔公司 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
SK8662000A3 (en) * 1997-12-12 2001-01-18 Abbott Lab Triazine angiogenesis inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2003289375A1 (en) * 2002-12-17 2004-07-09 Hamari Chemicals, Ltd Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
BRPI0620983B8 (pt) 2021-05-25
DK1971329T3 (en) 2017-12-04
KR101482686B1 (ko) 2015-01-14
PT1971329T (pt) 2017-11-24
BRPI0620983A2 (pt) 2011-11-29
FR2896161A1 (fr) 2007-07-20
WO2007079915A2 (en) 2007-07-19
CY1119872T1 (el) 2018-06-27
EA200801678A1 (ru) 2008-12-30
IL192595A (en) 2013-04-30
HUE037217T2 (hu) 2018-08-28
CA2636838C (en) 2015-05-05
CA2636838A1 (en) 2007-07-19
KR20080088629A (ko) 2008-10-02
BRPI0620983B1 (pt) 2019-09-17
CN101355931A (zh) 2009-01-28
LT1971329T (lt) 2018-01-25
EA016127B1 (ru) 2012-02-28
IL192595A0 (en) 2009-02-11
US8217040B2 (en) 2012-07-10
EP1971329B1 (en) 2017-10-11
AR059034A1 (es) 2008-03-12
FR2896161B1 (fr) 2008-04-04
US20100168115A1 (en) 2010-07-01
AU2006334732A1 (en) 2007-07-19
EP1971329A2 (en) 2008-09-24
PL1971329T3 (pl) 2018-03-30
WO2007079915A3 (en) 2007-08-30
SI1971329T1 (en) 2018-03-30
JP2009523140A (ja) 2009-06-18
ES2647912T3 (es) 2017-12-27
AU2006334732B2 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
EP1995056A4 (en) MULTILAYER BODY
EP2060391A4 (en) MULTILAYER BODY
GB0607270D0 (en) The pulsing blood supply
HUE026549T2 (hu) 1-N-azacikloalkil-3-fenoxipropán pszichotróp gyógyszerek elõállítására alkalmas származékai
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
EP2081483A4 (en) ANTIEXTRAVASATIONSKATHETER
ZA200903401B (en) The uses of the carboxy-amido-triazole compounds and salts thereof
HUP0700369A2 (en) Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en) Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
IL195971A0 (en) Use of defibrotide for the inhibition of heparanase
EP1976590A4 (en) CATHETER
HK1129206A1 (en) New medical use of triazine derivatives
ZA200806946B (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
IL197883A0 (en) Combination drug
GB0625783D0 (en) Medicament
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL195355A0 (en) Substituted pyrazinone derivatives for use as a medicine
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
PL380561A1 (pl) Sposób otrzymywania pochodnych antracyklin
HK1138189A1 (en) Use of a compound in the manufacture of a medicament for the treatment of leukaemia
GB0702895D0 (en) Delta 9 tetrahydrocannabinol derivatives
GB0615064D0 (en) Medicament
IL175571A0 (en) Use of non-catalytic form of heparanase and peptides thereof for reverising the anti-coagulant effects of heparinoids
GB0708326D0 (en) Triazine derivatives
GB0615814D0 (en) Medicament